Author Archives: JmaC

Growth charting the brain’s networks could provide a novel way to detect neurocognitive abnormalities such as impaired attention functioning in youth, researchers said. Resting-state functional neuroimaging of a small cohort of youth revealed deviations from normal patterns of brain maturation … Continue reading →

Mindfulness-based cognitive therapy (MBCT) was effective at reducing risk of relapse in patients with recurrent depression, especially in those with the most severe residual symptoms, a meta-analysis showed. Patients receiving MBCT had a significantly reduced risk of depressive relapse within … Continue reading →

More patients with serious psychological distress had insurance coverage following the Affordable Care Act, but that didn’t change whether they’d seen a healthcare professional recently, researchers reported. In an analysis of data from the National Health Interview Survey (NHIS), the … Continue reading →

WASHINGTON — The atypical antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada) may trigger loss of impulse control, leading to “compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex,” the FDA warned Tuesday. New warnings will be added … Continue reading →

Repeated infusions of ketamine “rapidly and robustly” decreased chronic thoughts of suicide in half of patients with treatment-resistant depression, secondary analysis from a preliminary open-label study showed. At the end of the series of infusions, 7 out of 14 patients … Continue reading →